Update on Rivaroxaban
Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to offer safe anticoagulation without the need f...
Main Authors: | Osama Moussa, Dipankar Chattopadhyay, Vish Bhattacharya |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2010-01-01
|
Series: | Clinical Medicine Insights: Blood Disorders |
Online Access: | https://doi.org/10.4137/CMBD.S5101 |
Similar Items
-
Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019-05-01) -
Postgraduate vascular surgery : the candidate's guide to the FRCS /
by: Bhattacharya, Vish, et al.
Published: (2010) -
DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
by: Rachel Ryu PharmD, BCPS
Published: (2022-12-01) -
Rivaroxaban in stable cardiovascular disease
by: Cahill, T, et al.
Published: (2018) -
Rivaroxaban and Hemostasis in Emergency Care
by: Jürgen Koscielny, et al.
Published: (2014-01-01)